Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Apr;141(8):1285-93.
doi: 10.1038/sj.bjp.0705762.

Role of serotonin in the pathophysiology of the irritable bowel syndrome

Michael D Crowell  1
Affiliations
Review

Role of serotonin in the pathophysiology of the irritable bowel syndrome

Michael D Crowell. Br J Pharmacol. 2004 Apr.

Abstract

The irritable bowel syndrome (IBS) is a complex disorder that is associated with altered gastrointestinal motility, secretion, and sensation. Serotonin (5-HT) is an important neurotransmitter and paracrine signalling molecule in the gastrointestinal tract. 5-HT release from enterochromaffin (EC) cells initiates peristaltic, secretory, vasodilatory, vagal and nociceptive reflexes. The enteric nervous system (ENS) comprises a semiautonomous effector system that is connected to the central autonomic network. Parasympathetic and sympathetic nerves modulate the ENS via afferent and efferent communications. Ongoing, bidirectional brain-gut interactions involving 5-HT pathways occur that significantly influence the effector systems. Altered 5-HT signalling may lead to both intestinal and extraintestinal symptoms in IBS. 5-HT directly and indirectly affects intestinal motor and secretory function and abnormalities may lead to either constipation or diarrhea. 5-HT modulates sensation and perception of visceral stimulation at peripheral and central sites. Therapeutic agents targeting altered 5-HT signalling may provide new, effective treatments for patients with IBS.

PubMed Disclaimer

References

    1. APPEL S., KUMLE A., MEIER R. Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit. Clin. Pharmacol. Ther. 1997;62:546–555. - PubMed
    1. AZPIROZ F., ENCK P., WHITEHEAD W.E. Anorectal functional testing: review of collective experience. Am. J. Gastroenterol. 2002;97:232–240. - PubMed
    1. BAIG M.K., ZHAO R.H., WOODHOUSE S.L., ABRAMSON S., SINGH J.J., WEISS E.G., NOGUERAS J.J., WEXNER S.D. Variability in serotonin and enterochromaffin cells in patients with colonic inertia and idiopathic diarrhoea as compared to normal controls. Colorectal. Dis. 2002;4:348–354. - PubMed
    1. BARDHAN K.D., BODEMAR G., GELDOF H., SCHUTZ E., HEATH A., MILLS J.G., JACQUES L.A. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. 2000;14:23–34. - PubMed
    1. BEARCROFT C.P., ANDRE E.A., FARTHING M.J. In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum; as segmental perfusion study. Ailment. Pharmacol. Ther. 1997;11:1109–1114. - PubMed

MeSH terms

LinkOut - more resources